The vascular bypass revolution

June 10, 2016

Coronary or peripheral bypasses are the most frequently performed vascular operations. Although one million patients per year and around the world, undergo this intervention, its failure rate reaches 50%, because of poor vessel healing, leading to vessel graft occlusion. To improve the outcome of bypasses, researchers from the University of Geneva (UNIGE) work together with medical doctors from the Lausanne University Hospital (CHUV). They developed a gel containing microparticles -'GeM', enabling the controlled release of a drug inhibiting cellular over-proliferation. Administered locally, directly on the bypass graft during surgery, this preventive treatment will reduce the risk of obstruction reoccurrence. This research can be read in The Journal of Controlled Release.

The vascular bypass allows a blocked artery to be bypassed by implanting a vessel removed from the patient, and this is done in order to create a deviation in circulation. However, in 50% of cases, excessive vascular cell proliferation, called hyperplasia, occurs around the suturing site of the transplanted vessel. Hyperplasia then leads to a decrease in blood flow within five years following the operation, requiring a new surgery. Today, doctors prescribe atorvastatin (ATV) orally against hyperplasia. However, this route of administration is not adapted to this pathology.

This is why Doctor François Saucy's team from CHUV joined forces with Florence Delie and Olivier Jordan, researchers at the Department of Pharmaceutical Sciences at UNIGE Faculty of Science. The goal: to find a way for local administration of ATV, that will remain available over a long time period, in order to overcome the disadvantages of high dosage taken orally. 'We immediately thought of a gel mixed with ATV, being directly applied on the vessel during surgery. Being viscous, it remains in place and enables local release, explains Florence Delie. 'But, we had an important challenge- doctors recommended the presence of the drug over a period of four weeks to avoid hyperplasia development, while the gel is only effective for three days'. Researchers from UNIGE have consequently added polymer microparticles containing ATV to the original formulation. These microparticles carry the encapsulated drug and gradually dissolve into the gel, therefore releasing ATV over one month.

The right dose in the right place

'It is about a controlled release system: the right dose at the right place, with the correct release profile, emphasises Olivier Jordan. 'We discovered that this formulation only works using the combination of, on one side, quickly released ATV mixed into the gel and on the other side, the microparticles, which act over the long term. There lies our innovation', adds Ioanna Mylonaki, researcher at UNIGE. 'Its use on patients is contemplated in five to ten years. Its efficacy would revolutionize the success rate of vascular bypasses.'
-end-


Université de Genève

Related Surgery Articles from Brightsurf:

Decision conflict before cancer surgery correlates with lower activity after surgery
Nearly one-third of cancer patients who decide to undergo surgery for their condition may have second thoughts, and this decision conflict may lead to less favorable treatment outcomes in both the near- and long-term, according to a team of investigators at Massachusetts General Hospital and Ariadne Labs.

Examining association between weight loss before bariatric surgery, risk of death after surgery
Researchers looked at whether a patient's body weight and weight loss before bariatric surgery were associated with risk of death within 30 days after surgery using data from nearly 500,000 patients in the US and Canada.

Guidelines for thyroid surgery published in Annals of Surgery
The first set of comprehensive, evidence-based clinical guidelines for surgical treatment of thyroid disease -- developed by an expert panel assembled by the American Association of Endocrine Surgeons (AAES) -- was published today by Annals of Surgery.

Colorectal surgery patients use fewer opioids, report less pain with enhanced recovery after surgery
Colorectal surgery patients who were a part of an enhanced recovery after surgery (ERAS) program had less pain, while using nearly half as many opioids, according to research being presented at the ANESTHESIOLOGY® 2019 annual meeting.

Video assisted lung surgery reduces complications and hospital stays compared to open surgery
Video-assisted thoracic surgery is associated with lower in-hospital complications and shorter length of stay compared with open surgery among British patients who were diagnosed at an early stage of lung cancer, according to research presented today the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

Most deaths related to noncardiac surgery occur after surgery and after discharge from hospital
It's not the operating room that is risky for patients undergoing noncardiac surgery; it's the recovery period.

Study looks at opioid use after knee surgery
A small study looked at whether reducing the number of opioid tablets prescribed after knee surgery would reduce postoperative use and if preoperative opioid-use education would reduce it even more.

Surgery patients are getting older every year
A new BJS (British Journal of Surgery) analysis reveals that people undergoing surgery in England are getting older at a faster rate than the general population.

Children requiring thyroid surgery have better outcomes at high-volume surgery centers
New research recently published in the Journal of Pediatric Surgery found that post-operative success rates of pediatric thyroid patients, particularly children who require a thyroidectomy, correlate with the institution's patient volume.

Do negative public attitudes toward weight loss surgery stop some patients from having surgery?
Most patients who qualify for weight loss surgery don't have the procedure despite its safety and effectiveness.

Read More: Surgery News and Surgery Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.